Clinical Research Directory

Inclusion Criteria: * Histologically or cytologically confirmed locally advanced or metastatic solid tumors or histopathologically confirmed NHL * Relapsed/refractory solid tumor or relapsed/refractory NHL who have progressed during or after standard therapy or for which treatment is not tolerated, not suitable, not available. * At least one evaluable or measurable lesion (as defined in the protocol). * ECOG Performance Status 0 or 1. * Life expectancy ≥12 weeks. * Adequate organ function (as defined in the protocol). * Reproductive criteria (as defined in the protocol). Exclusion Criteria: * Any clinically significant gastrointestinal (GI) abnormalities that may alter absorption. * Major surgery, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry. Radiation therapy within 2 weeks prior to study entry. * Adverse reactions from previous anti-tumor therapy have not yet recovered to ≤ grade 1(excluding hair loss, peripheral neurotoxicity caused by chemotherapy have recovered to ≤ grade 2 ). * Autologous hematopoietic stem cell transplantation was performed within 9 months prior to the first dose. * History of a second malignancy within 2 years (as defined in the protocol). * Active uncontrolled or symptomatic lung disease (as defined in the protocol). * Intracranial hypertension or active uncontrolled or symptomatic CNS metastases. * Known or suspected hypersensitivity to study medications. * Known active uncontrolled or symptomatic CNS metastases. * The investigator determined that the patient should not participate in the study. * Known mental illness or substance abuse that may disrupt therapy. * Clinically significant cardiac abnormalities (as defined in the protocol). * Gestating or Lactating women. * Pleural effusion, pericardial effusion or ascites that need diuretics or draining within 2 weeks prior to first dose. * The patient is currently using a drug known to be a strong inhibitor or inducer of CYP3A4.